Standard

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. / Haggenburg, Sabine; Lissenberg-Witte, Birgit I.; van Binnendijk, Rob S.; den Hartog, Gerco; Bhoekhan, Michel S.; Haverkate, Nienke J. E.; de Rooij, Dennis M.; van Meerloo, Johan; Cloos, Jacqueline; Kootstra, Neeltje A.; Wouters, Dorine; Weijers, Suzanne S.; van Leeuwen, Ester M. M.; Bontkes, Hetty J.; Tonouh-Aajoud, Saïda; Heemskerk, Mirjam H. M.; Sanders, Rogier W.; Roelandse-Koop, Elianne; Hofsink, Quincy; Groen, Kazimierz; Çetinel, Lucia; Schellekens, Louis; den Hartog, Yvonne M.; Toussaint, Belle; Kant, Iris M. J.; Graas, Thecla; de Pater, Emma; Dik, Willem A.; Engel, Marije D.; Pierie, Cheyenne R. N.; Janssen, Suzanne R.; van Dijkman, Edith; Poniman, Meliawati; Burger, Judith A.; Bouhuijs, Joey H.; Smits, Gaby; Rots, Nynke Y.; Zweegman, Sonja; Kater, Arnon P.; van Meerten, Tom; Mutsaers, Pim G. N. J.; van Doesum, Jaap A.; Broers, Annoek E. C.; van Gils, Marit J.; Goorhuis, Abraham; Rutten, Caroline E.; Hazenberg, Mette D.; Nijhof, Inger S.

In: Blood advances, Vol. 6, No. 5, 08.03.2022, p. 1537-1546.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Haggenburg, S, Lissenberg-Witte, BI, van Binnendijk, RS, den Hartog, G, Bhoekhan, MS, Haverkate, NJE, de Rooij, DM, van Meerloo, J, Cloos, J, Kootstra, NA, Wouters, D, Weijers, SS, van Leeuwen, EMM, Bontkes, HJ, Tonouh-Aajoud, S, Heemskerk, MHM, Sanders, RW, Roelandse-Koop, E, Hofsink, Q, Groen, K, Çetinel, L, Schellekens, L, den Hartog, YM, Toussaint, B, Kant, IMJ, Graas, T, de Pater, E, Dik, WA, Engel, MD, Pierie, CRN, Janssen, SR, van Dijkman, E, Poniman, M, Burger, JA, Bouhuijs, JH, Smits, G, Rots, NY, Zweegman, S, Kater, AP, van Meerten, T, Mutsaers, PGNJ, van Doesum, JA, Broers, AEC, van Gils, MJ, Goorhuis, A, Rutten, CE, Hazenberg, MD & Nijhof, IS 2022, 'Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients', Blood advances, vol. 6, no. 5, pp. 1537-1546. https://doi.org/10.1182/bloodadvances.2021006917

APA

Haggenburg, S., Lissenberg-Witte, B. I., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., de Rooij, D. M., van Meerloo, J., Cloos, J., Kootstra, N. A., Wouters, D., Weijers, S. S., van Leeuwen, E. M. M., Bontkes, H. J., Tonouh-Aajoud, S., Heemskerk, M. H. M., Sanders, R. W., Roelandse-Koop, E., Hofsink, Q., ... Nijhof, I. S. (2022). Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood advances, 6(5), 1537-1546. https://doi.org/10.1182/bloodadvances.2021006917

Vancouver

Author

Haggenburg, Sabine ; Lissenberg-Witte, Birgit I. ; van Binnendijk, Rob S. ; den Hartog, Gerco ; Bhoekhan, Michel S. ; Haverkate, Nienke J. E. ; de Rooij, Dennis M. ; van Meerloo, Johan ; Cloos, Jacqueline ; Kootstra, Neeltje A. ; Wouters, Dorine ; Weijers, Suzanne S. ; van Leeuwen, Ester M. M. ; Bontkes, Hetty J. ; Tonouh-Aajoud, Saïda ; Heemskerk, Mirjam H. M. ; Sanders, Rogier W. ; Roelandse-Koop, Elianne ; Hofsink, Quincy ; Groen, Kazimierz ; Çetinel, Lucia ; Schellekens, Louis ; den Hartog, Yvonne M. ; Toussaint, Belle ; Kant, Iris M. J. ; Graas, Thecla ; de Pater, Emma ; Dik, Willem A. ; Engel, Marije D. ; Pierie, Cheyenne R. N. ; Janssen, Suzanne R. ; van Dijkman, Edith ; Poniman, Meliawati ; Burger, Judith A. ; Bouhuijs, Joey H. ; Smits, Gaby ; Rots, Nynke Y. ; Zweegman, Sonja ; Kater, Arnon P. ; van Meerten, Tom ; Mutsaers, Pim G. N. J. ; van Doesum, Jaap A. ; Broers, Annoek E. C. ; van Gils, Marit J. ; Goorhuis, Abraham ; Rutten, Caroline E. ; Hazenberg, Mette D. ; Nijhof, Inger S. / Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. In: Blood advances. 2022 ; Vol. 6, No. 5. pp. 1537-1546.

BibTeX

@article{7852c6ff04c54aa0aef22e21e347359e,
title = "Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients",
abstract = "Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We prospectively quantified serum immunoglobulin G (IgG) antibodies to spike subunit 1 (S1) antigens during and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG $ 300 binding antibody units (BAUs)/mL was considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals, and it correlates with potent virus neutralization. Selected patients (n 5 723) were severely immunocompromised owing to their disease or treatment thereof. Nevertheless, .50% of patients obtained S1 IgG $ 300 BAUs/mL after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft-versus-host disease (cGVHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG $ 300 BAUs/mL. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses in patients with lymphoma, patients with CLL on ibrutinib, and chimeric antigen receptor T-cell recipients were low. The minimal time interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was,2 months for multiple myeloma, 8 months for lymphoma, and 4 to 6 months after allogeneic HCT. Serum IgG4, absolute B- and natural killer–cell number, and number of immunosuppressants predicted S1 IgG $ 300 BAUs/mL. Hematology patients on chemotherapy, shortly after HCT, or with cGVHD should not be precluded from vaccination. This trial was registered at Netherlands Trial Register as #NL9553.",
author = "Sabine Haggenburg and Lissenberg-Witte, {Birgit I.} and {van Binnendijk}, {Rob S.} and {den Hartog}, Gerco and Bhoekhan, {Michel S.} and Haverkate, {Nienke J. E.} and {de Rooij}, {Dennis M.} and {van Meerloo}, Johan and Jacqueline Cloos and Kootstra, {Neeltje A.} and Dorine Wouters and Weijers, {Suzanne S.} and {van Leeuwen}, {Ester M. M.} and Bontkes, {Hetty J.} and Sa{\"i}da Tonouh-Aajoud and Heemskerk, {Mirjam H. M.} and Sanders, {Rogier W.} and Elianne Roelandse-Koop and Quincy Hofsink and Kazimierz Groen and Lucia {\c C}etinel and Louis Schellekens and {den Hartog}, {Yvonne M.} and Belle Toussaint and Kant, {Iris M. J.} and Thecla Graas and {de Pater}, Emma and Dik, {Willem A.} and Engel, {Marije D.} and Pierie, {Cheyenne R. N.} and Janssen, {Suzanne R.} and {van Dijkman}, Edith and Meliawati Poniman and Burger, {Judith A.} and Bouhuijs, {Joey H.} and Gaby Smits and Rots, {Nynke Y.} and Sonja Zweegman and Kater, {Arnon P.} and {van Meerten}, Tom and Mutsaers, {Pim G. N. J.} and {van Doesum}, {Jaap A.} and Broers, {Annoek E. C.} and {van Gils}, {Marit J.} and Abraham Goorhuis and Rutten, {Caroline E.} and Hazenberg, {Mette D.} and Nijhof, {Inger S.}",
note = "Funding Information: Funding support for this article was provided by the Dutch Research Council (NWO / ZonMW) (10430072010009) Funding Information: This study was financially supported by the Dutch Research Council (NWO/ZonMW, grant 10430072010009) and Amsterdam UMC. Publisher Copyright: {\textcopyright} 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.",
year = "2022",
month = mar,
day = "8",
doi = "10.1182/bloodadvances.2021006917",
language = "English",
volume = "6",
pages = "1537--1546",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "5",

}

RIS

TY - JOUR

T1 - Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

AU - Haggenburg, Sabine

AU - Lissenberg-Witte, Birgit I.

AU - van Binnendijk, Rob S.

AU - den Hartog, Gerco

AU - Bhoekhan, Michel S.

AU - Haverkate, Nienke J. E.

AU - de Rooij, Dennis M.

AU - van Meerloo, Johan

AU - Cloos, Jacqueline

AU - Kootstra, Neeltje A.

AU - Wouters, Dorine

AU - Weijers, Suzanne S.

AU - van Leeuwen, Ester M. M.

AU - Bontkes, Hetty J.

AU - Tonouh-Aajoud, Saïda

AU - Heemskerk, Mirjam H. M.

AU - Sanders, Rogier W.

AU - Roelandse-Koop, Elianne

AU - Hofsink, Quincy

AU - Groen, Kazimierz

AU - Çetinel, Lucia

AU - Schellekens, Louis

AU - den Hartog, Yvonne M.

AU - Toussaint, Belle

AU - Kant, Iris M. J.

AU - Graas, Thecla

AU - de Pater, Emma

AU - Dik, Willem A.

AU - Engel, Marije D.

AU - Pierie, Cheyenne R. N.

AU - Janssen, Suzanne R.

AU - van Dijkman, Edith

AU - Poniman, Meliawati

AU - Burger, Judith A.

AU - Bouhuijs, Joey H.

AU - Smits, Gaby

AU - Rots, Nynke Y.

AU - Zweegman, Sonja

AU - Kater, Arnon P.

AU - van Meerten, Tom

AU - Mutsaers, Pim G. N. J.

AU - van Doesum, Jaap A.

AU - Broers, Annoek E. C.

AU - van Gils, Marit J.

AU - Goorhuis, Abraham

AU - Rutten, Caroline E.

AU - Hazenberg, Mette D.

AU - Nijhof, Inger S.

N1 - Funding Information: Funding support for this article was provided by the Dutch Research Council (NWO / ZonMW) (10430072010009) Funding Information: This study was financially supported by the Dutch Research Council (NWO/ZonMW, grant 10430072010009) and Amsterdam UMC. Publisher Copyright: © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PY - 2022/3/8

Y1 - 2022/3/8

N2 - Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We prospectively quantified serum immunoglobulin G (IgG) antibodies to spike subunit 1 (S1) antigens during and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG $ 300 binding antibody units (BAUs)/mL was considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals, and it correlates with potent virus neutralization. Selected patients (n 5 723) were severely immunocompromised owing to their disease or treatment thereof. Nevertheless, .50% of patients obtained S1 IgG $ 300 BAUs/mL after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft-versus-host disease (cGVHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG $ 300 BAUs/mL. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses in patients with lymphoma, patients with CLL on ibrutinib, and chimeric antigen receptor T-cell recipients were low. The minimal time interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was,2 months for multiple myeloma, 8 months for lymphoma, and 4 to 6 months after allogeneic HCT. Serum IgG4, absolute B- and natural killer–cell number, and number of immunosuppressants predicted S1 IgG $ 300 BAUs/mL. Hematology patients on chemotherapy, shortly after HCT, or with cGVHD should not be precluded from vaccination. This trial was registered at Netherlands Trial Register as #NL9553.

AB - Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We prospectively quantified serum immunoglobulin G (IgG) antibodies to spike subunit 1 (S1) antigens during and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG $ 300 binding antibody units (BAUs)/mL was considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals, and it correlates with potent virus neutralization. Selected patients (n 5 723) were severely immunocompromised owing to their disease or treatment thereof. Nevertheless, .50% of patients obtained S1 IgG $ 300 BAUs/mL after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft-versus-host disease (cGVHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG $ 300 BAUs/mL. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses in patients with lymphoma, patients with CLL on ibrutinib, and chimeric antigen receptor T-cell recipients were low. The minimal time interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was,2 months for multiple myeloma, 8 months for lymphoma, and 4 to 6 months after allogeneic HCT. Serum IgG4, absolute B- and natural killer–cell number, and number of immunosuppressants predicted S1 IgG $ 300 BAUs/mL. Hematology patients on chemotherapy, shortly after HCT, or with cGVHD should not be precluded from vaccination. This trial was registered at Netherlands Trial Register as #NL9553.

UR - http://www.scopus.com/inward/record.url?scp=85126092229&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2021006917

DO - 10.1182/bloodadvances.2021006917

M3 - Article

C2 - 35114690

VL - 6

SP - 1537

EP - 1546

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 5

ER -

ID: 22157015